In some human cancers, BRD4 has been found to be recruited into enhancers co-occupied by mutated p53 and to support the synthesis of enhancer-directed transcripts (eRNAs) in response to chronic immune signaling (Rahnamoun et al., 2018). This evidence concerns the gene TP53 and cancer.